Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)
A rights offer for existing shareholders is now open.
Full details are available here.
Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs
Recent news and media
The Dimerix Limited (ASX: DXB) Entitlement Offer or ‘Rights Issue’ to raise $5.5 million is due to close this Friday, 19 January 2018 [...]
Dimerix Limited announces top-line results from a recent pharmacokinetic (PK) study of an extended release tablet formulation for their DMX-200 program [...]